Top

Published in:

01-05-2022 | Prostate Cancer | Review Article

Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function

Authors: A. B. Reiss, U. Saeedullah, D. J. Grossfeld, A. D. Glass, A. Pinkhasov, A. E. Katz

Published in: Clinical and Translational Oncology | Issue 5/2022

Abstract

Prostate cancer is the second most common form of cancer in men. For advanced, high risk prostate cancer, androgen deprivation therapy (ADT) is the preferred treatment and can induce remission, but resistance to ADT brings biochemical recurrence and progression of cancer. ADT brings adverse effects such as erectile dysfunction, decreased libido, and diminished physical strength. It is estimated that between 25 and 50% of men on ADT manifest some form of cognitive dysfunction that may be self-reported or reported by a family member. There is concern that impaired cognitive function with ADT is due to loss of testosterone support. Testosterone and its metabolites are known to possess neuroprotective properties. While a direct causal relationship between ADT and cognitive decline in prostate cancer patients has not been established, this review describes the controversy surrounding the possible connection between ADT and neurocognitive deterioration. The cellular and molecular mechanisms believed to underlie the protection of neuronal integrity by androgens are discussed. Results from animal models and human clinical studies are presented. Finally, we call attention to lifestyle modifications that may minimize cognitive issues in prostate cancer patients.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Bhanji Y, Isaacs WB, Xu J, Cooney KA. Prostate cancer predisposition. Urol Clin North Am. 2021;48:283–96. https://doi.org/10.1016/j.ucl.2021.03.001.CrossRefPubMed

Cózar JM, Hernández C, Miñana B, Morote J, Alvarez-Cubero MJ. The role of prostate-specific antigen in light of new scientific evidence: an update in 2020. Actas Urol Esp. 2021;45:21–9. https://doi.org/10.1016/j.acuro.2020.09.005.CrossRefPubMed

Ahmed A, Ali S, Sarkar FH. Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol. 2014;229:271–6. https://doi.org/10.1002/jcp.24456.CrossRefPubMed

Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9(Suppl 1):S3–8.PubMedPubMedCentral

Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas. 2011;69:322–37. https://doi.org/10.1016/j.maturitas.2011.05.012.CrossRefPubMed

Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Netw Open. 2019;2: e196562. https://doi.org/10.1001/jamanetworkopen.2019.6562.CrossRefPubMedPubMedCentral

Alonso-Quiñones H, Stish BJ, Aakre JA, Hagen CE, Petersen RC, Mielke MM. Androgen deprivation therapy use and risk of mild cognitive impairment in prostate cancer patients. Alzheimer Dis Assoc Disord. 2021;35:44–7. https://doi.org/10.1097/WAD.0000000000000415.CrossRefPubMedPubMedCentral

Marandino L, Vignani F, Buttigliero C, Gamba T, Necchi A, Tucci M, et al. Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: a systematic review. Cancers (Basel). 2020;12:2568. https://doi.org/10.3390/cancers12092568.CrossRef

10.

Andela CD, Matte R, Jazet IM, Zonneveld WC, Schoones JW, Meinders AE. Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: a systematic review. Int J Urol. 2021;28:786–98. https://doi.org/10.1111/iju.14596.CrossRefPubMed

11.

Welch HG, Albertsen PC. Reconsidering prostate cancer mortality—the future of PSA screening. N Engl J Med. 2020;382:1557–63. https://doi.org/10.1056/NEJMms1914228.CrossRefPubMed

12.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Int Med. 2008;148:435–48. https://doi.org/10.7326/0003-4819-148-6-200803180-00209.CrossRefPubMed

13.

Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, et al. Radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up. N Engl J Med. 2018;379:2319–29. https://doi.org/10.1056/NEJMoa1807801.CrossRefPubMed

14.

Carbonara U, Srinath M, Crocerossa F, Ferro M, Cantiello F, Lucarelli G, et al. Robot-assisted radical prostatectomy versus standard laparoscopic radical prostatectomy: an evidence-based analysis of comparative outcomes. World J Urol. 2021. https://doi.org/10.1007/s00345-021-03687-5.CrossRefPubMed

15.

Kang SG, Shim JS, Onol F, Bhat KRS, Patel VR. Lessons learned from 12,000 robotic radical prostatectomies: is the journey as important as the outcome? Investig Clin Urol. 2020;61:1–10. https://doi.org/10.4111/icu.2020.61.1.1.CrossRefPubMedPubMedCentral

16.

Golbari NM, Katz AE. Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review. Curr Urol Rep. 2017;18:63. https://doi.org/10.1007/s11934-017-0709-4.CrossRefPubMed

17.

Garje R, Chennamadhavuni A, Mott SL, Chambers IM, Gellhaus P, Zakharia Y, et al. Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer. Clin Genitourin Cancer. 2020;18:e157–66. https://doi.org/10.1016/j.clgc.2019.09.020.CrossRefPubMed

18.

Sountoulides P, Rountos T. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol. 2013;2013:1–8. https://doi.org/10.1155/2013/240108.CrossRef

19.

Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, et al. Clinical outcomes for patients with Gleason Score 9–10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis. Eur Urol. 2017;71:766–73. https://doi.org/10.1016/j.eururo.2016.06.046.CrossRefPubMed

20.

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019;75:285–93. https://doi.org/10.1016/j.eururo.2018.07.035.CrossRefPubMed

21.

Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31:3800–6. https://doi.org/10.1200/JCO.2012.44.6716.CrossRefPubMedPubMedCentral

22.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18. https://doi.org/10.1056/NEJMoa1715546.CrossRefPubMed

23.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ubirajara F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74. https://doi.org/10.1056/NEJMoa1800536.CrossRefPubMedPubMedCentral

24.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974–86. https://doi.org/10.1200/JCO.19.00799.CrossRefPubMedPubMedCentral

25.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, ARAMIS Investigators, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235–46. https://doi.org/10.1056/NEJMoa1815671.CrossRefPubMed

26.

O’Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317–25. https://doi.org/10.1038/sj.bjc.6601879.CrossRefPubMedPubMedCentral

27.

Shpilsky J, Stevens J, Bubley G. An up-to-date evaluation of abiraterone for the treatment of prostate cancer. Expert Opin Pharmacother. 2021. https://doi.org/10.1080/14656566.2021.1915287.CrossRefPubMed

28.

Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92. https://doi.org/10.1016/S1470-2045(12)70379-0.CrossRefPubMed

29.

Paudel R, Ferrante S, Qi J, Dunn RL, Berry DL, Semerjian A, Michigan Urological Surgery Improvement Collaborative, et al. Patient preferences and treatment decisions for prostate cancer: results from a statewide urological quality improvement collaborative. Urology. 2021;155:55–61. https://doi.org/10.1016/j.urology.2021.04.020.CrossRefPubMed

30.

López-Campos F, González-San Segundo C, Conde-Moreno AJ, Couñago F. Metastatic hormone-sensitive prostate cancer: how should it be treated? World J Clin Oncol. 2021;12:43–9. https://doi.org/10.5306/wjco.v12.i2.43.CrossRefPubMedPubMedCentral

31.

Mhaouty-Kodja S. Role of the androgen receptor in the central nervous system. Mol Cell Endocrinol. 2018;465:103–12. https://doi.org/10.1016/j.mce.2017.08.001.CrossRefPubMed

32.

Grimm A, Schmitt K, Lang UE, Mensah-Nyagan AG, Eckert A. Improvement of neuronal bioenergetics by neurosteroids: implications for age-related neurodegenerative disorders. Biochim Biophys Acta. 2014;1842:2427–38. https://doi.org/10.1016/j.bbadis.2014.09.013.CrossRefPubMed

33.

Ishihara Y, Fujitani N, Sakurai H, Takemoto T, Ikeda-Ishihara N, Mori-Yasumoto K, et al. Effects of sex steroid hormones and their metabolites on neuronal injury caused by oxygen-glucose deprivation/reoxygenation in organotypic hippocampal slice cultures. Steroids. 2016;113:71–7. https://doi.org/10.1016/j.steroids.2016.06.004.CrossRefPubMed

34.

Son SW, Lee JS, Kim HG, Kim DW, Ahn YC, Son CG. Testosterone depletion increases the susceptibility of brain tissue to oxidative damage in a restraint stress mouse model. J Neurochem. 2016;136:106–17. https://doi.org/10.1111/jnc.13371.CrossRefPubMed

35.

Beyenburg S, Watzka M, Clusmann H, Blumcke I, Bidlingmaier F, Elger CE, et al. Androgen receptor mRNA expression in the human hippocampus. Neurosci Lett. 2000;294:25–8. https://doi.org/10.1016/s0304-3940(00)01542-1.CrossRefPubMed

36.

Ou J, Wu Y, Hu Y, Gao X, Li H, Tobler PN. Testosterone reduces generosity through cortical and subcortical mechanisms. Proc Natl Acad Sci USA. 2021;23(118):12. https://doi.org/10.1073/pnas.2021745118.CrossRef

37.

Choi JC, Park YH, Park SK, Lee JS, Kim J, Choi JI, et al. Testosterone effects on pain and brain activation patterns. Acta Anaesthesiol Scand. 2017;61:668–75. https://doi.org/10.1111/aas.12908.CrossRefPubMed

38.

Knutson KM, Gotts SJ, Wassermann EM, Lewis JD. Testosterone and resting state connectivity of the parahippocampal gyrus in men with history of deployment-related mild traumatic brain injury. Mil Med. 2020;185:e1750–8. https://doi.org/10.1093/milmed/usaa142.CrossRefPubMedPubMedCentral

39.

Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2839–53.PubMed

40.

Carrier N, Saland SK, Duclot F, He H, Mercer R, Kabbaj M. The anxiolytic and antidepressant-like effects of testosterone and estrogen in gonadectomized male rats. Biol Psychiatry. 2015;78:259–69. https://doi.org/10.1016/j.biopsych.2014.12.024.CrossRefPubMedPubMedCentral

41.

Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, et al. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. Addiction. 2015;110:823–31.PubMedPubMedCentralCrossRef

42.

Edinger KL, Frye CA. Androgens’ performance-enhancing effects in the inhibitory avoidance and water maze tasks may involve actions at intracellular androgen receptors in the dorsal hippocampus. Neurobiol Learn Mem. 2007;87:201–8.PubMedCrossRef

43.

Seyedreza P, Alireza MN, Seyedebrahim H. Role of testosterone in memory impairment of Alzheimer disease induced by streptozotocin in male rats. Daru. 2012;20:98. https://doi.org/10.1186/2008-2231-20-98.CrossRefPubMedPubMedCentral

44.

Rizk A, Robertson J, Raber J. Behavioral performance of tfm mice supports the beneficial role of androgen receptors in spatial learning and memory. Brain Res. 2005;1034:132–8.PubMedCrossRef

45.

Naghdi N, Majlessi N, Bozorgmehr T. The effect of intrahippocampal injection of testosterone enanthate (an androgen receptor agonist) and anisomycin (protein synthesis inhibitor) on spatial learning and memory in adult, male rats. Behav Brain Res. 2005;156:263–8.PubMedCrossRef

46.

Hatanaka Y, Hojo Y, Mukai H, Murakami G, Komatsuzaki Y, Kim J, et al. Rapid increase of spines by dihydrotestosterone and testosterone in hippocampal neurons: dependence on synaptic androgen receptor and kinase networks. Brain Res. 2015;1621:121–32.PubMedCrossRef

47.

Mueller SC, Verwilst T, Van Branteghem A, T’Sjoen G, Cools M. The contribution of the androgen receptor (AR) in human spatial learning and memory: a study in women with complete androgen insensitivity syndrome (CAIS). Horm Behav. 2016;78:121–6.PubMedCrossRef

48.

Carson CC. Effects of testosterone on cognition and mood in male patients with mild Alzheimer’s disease and elderly men. Curr Urol Rep. 2006;7:471–2.PubMedCrossRef

49.

Lee HH, Park S, Joung JY, Kim SH. How does androgen deprivation therapy affect mental health including cognitive dysfunction in patients with prostate cancer? World J Mens Health. 2020. https://doi.org/10.5534/wjmh.200092.CrossRefPubMedPubMedCentral

50.

Buskbjerg CR, Amidi A, Buus S, Gravholt CH, HadiHosseini SM, Zachariae R. Androgen deprivation therapy and cognitive decline-associations with brain connectomes, endocrine status, and risk genotypes. Prostate Cancer Prostatic Dis. 2021. https://doi.org/10.1038/s41391-021-00398-1.CrossRefPubMed

51.

Tae BS, Jeon BJ, Shin SH, Choi H, Bae JH, Park JY. Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: a nationwide population-based study using the National Health Insurance Service Database. Cancer Res Treat. 2019;51:593–602.PubMedCrossRef

52.

Treanor CJ, Li J, Donnelly M. Cognitive impairment among prostate cancer patients: an overview of reviews. Eur J Cancer Care. 2016;26:e12642.CrossRef

53.

Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018;199:1417–25.PubMedCrossRef

54.

Kluger J, Roy A, Chao HH. Androgen deprivation therapy and cognitive function in prostate cancer. Curr Oncol Rep. 2020;22:24.PubMedCrossRef

55.

Gunlusoy B, Ceylan Y, Koskderelioglu A, Gedizlioglu M, Degirmenci T, Ortan P, et al. Cognitive effects of androgen deprivation therapy in men with advanced prostate cancer. Urology. 2017;103:167–72.PubMedCrossRef

56.

Hsu B, Cumming RG, Waite LM, Blyth FM, Naganathan V, Le Couteur DG, et al. Longitudinal relationships between reproductive hormones and cognitive decline in older men: the concord health and ageing in men project. J Clin Endocrinol Metab. 2015;100:2223–30. https://doi.org/10.1210/jc.2015-1016.CrossRefPubMed

57.

Lv W, Du N, Liu Y, Fan X, Wang Y, Jia X, et al. Low testosterone level and risk of Alzheimer’s disease in the elderly men: a systematic review and meta-analysis. Mol Neurobiol. 2016;53:2679–84.PubMedCrossRef

58.

McGinty HL, Phillips KM, Jim HS, Cessna JM, Asvat Y, Cases MG, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22:2271–80.PubMedPubMedCentralCrossRef

59.

Sánchez-Martínez V, Buigues C, Navarro-Martínez R, García-Villodre L, Jeghalef N, Serrano-Carrascosa M, et al. Analysis of brain functions in men with prostate cancer under androgen deprivation therapy: a one-year longitudinal study. Life (Basel). 2021;10(11):227.

60.

Cinar O, Turunc T, Kazaz IO, Yildirim O, Deliktas H, Cihan A, et al. Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: a multicentric, prospective study of the Society of Urological Surgery Andrology group. Int J Clin Pract. 2021;75:e14095.PubMedCrossRef

61.

Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res. 2004;10:7575–82.PubMedCrossRef

62.

Rosario ER, Pike CJ. Androgen regulation of β-amyloid protein and the risk of Alzheimer’s disease. Brain Res Rev. 2008;57:444–53.PubMedCrossRef

63.

Yan XS, Yang ZJ, Jia JX, Song W, Fang X, Cai ZP, et al. Protective mechanism of testosterone on cognitive impairment in a rat model of Alzheimer’s disease. Neural Regen Res. 2019;14:649–57.PubMedPubMedCentralCrossRef

64.

Hammond J, Le Q, Goodyer C, Gelfand M, Trifor M, LeBlanc A. Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem. 2001;77:1319–26.PubMedCrossRef

65.

Thomas P. Membrane androgen receptors unrelated to nuclear steroid receptors. Endocrinology. 2019;160:772–81.PubMedCrossRef

66.

Garza-Contreras J, Duong P, Snyder BD, Schreihofer DA, Cunningham RL. Presence of Androgen Receptor Variant in Neuronal Lipid Rafts. eNeuro. 2017;4(4):109–17.CrossRef

67.

Labrie F. Intracrinology. Mol Cell Endocrinol. 1991;78:C113–8.PubMedCrossRef

68.

Boutin S, Roy J, Maltais R, Poirier D. Formation of 5α-dihydrotestosterone from 5α-androstane-3α,17β-diol in prostate cancer LAPC-4 cells—identifying inhibitors of non-classical pathways producing the most potent androgen. Bioorg Med Chem Lett. 2020;30: 126783. https://doi.org/10.1016/j.bmcl.2019.126783.CrossRefPubMed

69.

Vis AN, Schröder FH. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase. BJU Int. 2009;104:1191–7.PubMedCrossRef

70.

AzhagiyaSingam ER, Tachachartvanich P, La Merrill MA, Smith MT, Durkin KA. Structural dynamics of agonist and antagonist binding to the androgen receptor. J Phys Chem B. 2019;123:7657–66.CrossRef

71.

Matsumoto A. Hormonally induced neuronal plasticity in the adult motoneurons. Brain Res Bull. 1997;44:539–47.PubMedCrossRef

72.

Leranth C, Petnehazy O, MacLusky NJ. Gonadal hormones affect spine synaptic density in the CA1 hippocampal subfield of male rats. J Neurosci. 2003;23:1588–92.PubMedPubMedCentralCrossRef

73.

Pan W, Han S, Kang L, Li S, Du J, Cui H. Effects of dihydrotestosterone on synaptic plasticity of the hippocampus in mild cognitive impairment male SAMP8 mice. Exp Ther Med. 2016;12:1455–63.PubMedPubMedCentralCrossRef

74.

Lim D, Flicker L, Dharamarajan A, Martins RN. Can testosterone replacement decrease the memory problem of old age? Med Hypotheses. 2003;60:893–6. https://doi.org/10.1016/s0306-9877(03)00072-0.CrossRefPubMed

75.

Cherrier MM, Asthana SM, Plymate SM, Baker L, Matsumoto AM, Peskind E, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57:80–8.PubMedCrossRef

76.

Ahlbom E, Prins GS, Ceccatelli S. Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Res. 2001;892:255–62.PubMedCrossRef

77.

Muthu SJ, Seppan P. Apoptosis in hippocampal tissue induced by oxidative stress in testosterone deprived male rats. Aging Male. 2020;23:1598–610.PubMedCrossRef

78.

Nguyen TV, Jayaraman A, Quaglino A, Pike CJ. Androgens selectively protect against apoptosis in hippocampal neurons. J Neuroendocrinol. 2010;22:1013–22.PubMedPubMedCentralCrossRef

79.

Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017;35:183–91.PubMedCrossRef

80.

Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, et al. Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease. Mol Psychiatry. 2014;19:69–75.PubMedCrossRef

81.

Kulichikhin KY, Fedotov SA, Rubel MS, Zalutskaya NM, Zobnina AE, Malikova OA, et al. Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins. Prion. 2021;15:56–69.PubMedPubMedCentralCrossRef

82.

Lau CF, Ho YS, Hung CH, Wuwongse S, Poon CH, Chiu K, et al. Protective effects of testosterone on presynaptic terminals against oligomeric β-amyloid peptide in primary culture of hippocampal neurons. Biomed Res Int. 2014;2014:103906.PubMedPubMedCentralCrossRef

83.

Yao M, Nguyen TV, Rosario ER, Ramsden M, Pike CJ. Androgens regulate neprilysin expression: role in reducing beta-amyloid levels. J Neurochem. 2008;105:2477–88.PubMedCrossRef

84.

Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett. 2003;350:113–6.PubMedCrossRef

85.

Voskobiynyk Y, Roth JR, Cochran JN, Rush T, Carullo NV, Mesina JS, et al. Alzheimer’s disease risk gene BIN1 induces Tau-dependent network hyperexcitability. Elife. 2020;13(9): e57354. https://doi.org/10.7554/eLife.57354.CrossRef

86.

Lehrer S, Rheinstein PH. Alzheimer gene BIN1 may simultaneously influence dementia risk and androgen deprivation therapy dosage in prostate cancer. Am J Clin Oncol. 2020;43:685–9.PubMedPubMedCentralCrossRef

87.

Cheung AS, Hoermann R, Dupuis P, Joon DL, Zajac JD, Grossmann M. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur J Endocrinol. 2016;175:229–37.PubMedCrossRef

88.

Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013;189:S34-42.PubMedCrossRef

89.

Thomas HR, Chen MH, D’Amico AV, Bennett CL, Kattan MW, Sartor O, et al. Association between androgen deprivation therapy and patient-reported depression in men with recurrent prostate cancer. Clin Genitourin Cancer. 2018;16:313–7.PubMedCrossRef

90.

Wang L, Zhou Y, Chen D, Lee TH. Peptidyl-prolyl cis/trans isomerase Pin1 and Alzheimer’s disease. Front Cell Dev Biol. 2020;8:355. https://doi.org/10.3389/fcell.2020.00355.CrossRefPubMedPubMedCentral

91.

Lanni C, Masi M, Racchi M, Govoni S. Cancer and Alzheimer’s disease inverse relationship: an age-associated diverging derailment of shared pathways. Mol Psychiatry. 2021;26:280–95.PubMedCrossRef

92.

Launer BM, Lloyd GL. Sociodemographic index and global trends in prostate cancer: 1990–2017. Prostate. 2021;81:825–31.PubMedCrossRef

93.

Eliasson L, de Freitas HM, Dearden L, Calimlim B, Lloyd AJ. Patients’ preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment. Clin Ther. 2017;39:723–37.PubMedCrossRef

94.

Sharp AM, Lertphinyowong S, Yee SS, Paredes D, Gelfond J, Johnson-Pais TL, et al. Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer. Psychopharmacology. 2019;236:3183–95.PubMedPubMedCentralCrossRef

95.

Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013;111:543–8.PubMedCrossRef

96.

Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2:453–61.PubMedPubMedCentralCrossRef

97.

Focht BC, Lucas AR, Grainger E, Simpson C, Fairman CM, Thomas-Ahner JM, et al. Effects of a group-mediated cognitive behavioral lifestyle intervention on select social cognitive outcomes in prostate cancer patients undergoing androgen deprivation therapy. Integr Cancer Ther. 2019;18:1534735419893764.PubMedPubMedCentralCrossRef

98.

Wibowo E, Wassersug RJ, Robinson JW, Matthew A, McLeod D, Walker LM. How are patients with prostate cancer managing androgen deprivation therapy side effects? Clin Genitourin Cancer. 2019;17:e408–19.PubMedCrossRef

99.

Cormie P, Zopf EM. Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer. Urol Oncol. 2020;38:62–70.PubMedCrossRef

100.

Garland SN, Savard J, Eisel SL, Wassersug RJ, Rockwood NJ, Thoms J, et al. A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer. Cancer. 2021. https://doi.org/10.1002/cncr.33850.CrossRefPubMed

Title: Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function
Authors: A. B. Reiss
U. Saeedullah
D. J. Grossfeld
A. D. Glass
A. Pinkhasov
A. E. Katz
Publication date: 01-05-2022
Publisher: Springer International Publishing
Keywords: Prostate Cancer
Erectile Dysfunction
Prostate Cancer
Alzheimer's Disease
Alzheimer's Disease
Androgens
Testosterone
Stanolone
Published in: Clinical and Translational Oncology / Issue 5/2022
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-021-02727-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2022

Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma

Bone marrow mesenchymal stem cells promote the progression of prostate cancer through the SDF-1/CXCR4 axis in vivo and vitro

Analgesic effects of low-dose radiotherapy in greater trochanteric pain syndrome: results in a clinical series of 155 patients with recurrent or refractory symptoms

BRCA2 deficiency increases sensitivity of medulloblastoma to Olaparib by inhibiting RAD51-mediated DNA damage repair system

Bacterial driver–passenger model in biofilms: a new mechanism in the development of colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer